Most of the current antidepressants for major depressive disorder (MDD) are based upon the
monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction
has been implicated in the pathophysiology of depression. Therefore, this study will examine
the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE)
in the treatment of MDD in the adults.